Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Subscribe To Our Newsletter & Stay Updated